Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Cytosorbents Corp (CTSO)

CytoSorbents Q2 revenue flat at $9.6 million; operating loss narrows 27%

Positive Impact 3 of 5 earnings Written later

CytoSorbents furnished an investor presentation for its Q2 2026 earnings call held August 6, 2026. Product revenue was flat year over year at $9.6 million, while gross margin rose to 73% from 71% and the operating loss narrowed to $2.6 million from $3.6 million. The company continues to expect operating cash flow breakeven in the second half of 2026.

Key points

  • Q2 2026 product revenue was $9.6 million, unchanged from the prior year; Germany sales fell 24% to $2.5 million.
  • Gross margin rose to 73% from 71%, and total operating expenses fell to $9.7 million from $10.4 million.
  • Adjusted net loss narrowed 22% to $2.9 million ($0.05 per share) and adjusted EBITDA loss narrowed 38% to $1.6 million.
  • Cash, cash equivalents and restricted cash were $5.9 million at Q2 2026, down from $6.3 million at Q1 2026, after a $0.4 million net operating cash burn.

The filing

CompanyCytosorbents Corp (CTSO)
Form8-K, current report
Filed with the SECAug 7, 2026, 4:06 PM ET
Accession number0001104659-26-092691

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.